YC W24
ParcelBio
Elevated mRNA for transformative medicines.
About
ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.
Founders
- David Weinberg
- Chris Carlson
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in ParcelBio.
See family office activityIndustry & Focus
HealthcareTherapeuticsGene TherapySynthetic BiologyBiotechDrug discovery